Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018)

Akebia Therapeutics (AKBA) reported Long-Term Investments of $245000.0 for Q4 2018, down 99.51% quarter-over-quarter from $49.6 million in Q4 2015.

Akebia Therapeutics (AKBA) Long-Term Investments (2015 - 2018) Analysis & Trends

Akebia Therapeutics (AKBA) has 2 years of Long-Term Investments data on file, last reported at $245000.0 in Q4 2018.

Long-Term Investments for Q4 2018 came in at $245000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2018 was $245000.0 (changed N/A YoY), and the FY2018 annual result was $245000.0, changed N/A from the prior year.
Long-Term Investments fell to $245000.0 in Q4 2018 per AKBA's latest filing, from $49.6 million in the prior quarter.
Over five years, Long-Term Investments peaked at $51.0 million in Q3 2015 and troughed at $245000.0 in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Teva Pharmaceutical Industries	39.97 Bn	36.23 Bn	1.97 Bn	-
2	Zoetis	33.59 Bn	31.65 Bn	1.62 Bn	-
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	1.32 Bn
4	Neurocrine Biosciences	16.10 Bn	14.78 Bn	800.70 Mn	1.33 Bn
5	Aurora Cannabis	15.56 Bn	15.47 Bn	21.72 Mn	8.83 Mn
6	Elanco Animal Health	12.04 Bn	11.61 Bn	785.00 Mn	-
7	Alkermes	7.36 Bn	6.84 Bn	-116.06 Mn	26.36 Mn
8	Lantheus Holdings	6.74 Bn	6.24 Bn	230.92 Mn	1.90 Mn
9	Liquidia	6.27 Bn	6.04 Bn	121.79 Mn	-
10	Akebia Therapeutics	245.66 Mn	83.06 Mn	41.25 Mn	-

Download Data